Table 6 Overview of [68Ga]Ga-PSMA-11 productions (EOS)
From: Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target
Site | HNO3 [mol/L] | I [μA] | Beam time [min] | N | Product activity | Notes | |
|---|---|---|---|---|---|---|---|
[GBq] | [mCi] | ||||||
UM | 0.2 | 30–40 | 60 | 3 | 1.6 ± 0.3 | 43 ± 9 | Validation runs |
UM | 0.2 | 30–40 | 60 | 35 | 1.7 ± 0.2 | 45 ± 6 | Clinical |
GEMS | 0.3 | 30 | 64 ± 4 | 3 | 2.1 ± 0.4 | 57 ± 10 | R&D efforts |
RPA | 0.3 | 35 | 60 | 14 | 1.6 ± 0.1 | 44 ± 3 | Final validation and clinical (5) runs |